NBY vs PRPH vs QDEL vs AYTU

For growth investors, Aytu BioPharma, Inc.

(AYTU) is the stronger pick with 1. 8% revenue growth year-over-year, versus -84. 7% for ProPhase Labs, Inc. (PRPH). Analysts rate QuidelOrtho Corporation (QDEL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ProPhase Labs, Inc.

(PRPH) delivered a total return of -63. 2%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: PRPH returned +37. 5% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aytu BioPharma, Inc.

(AYTU) is the lower-risk stock at 1. 27β versus QuidelOrtho Corporation's 2. 59β — meaning QDEL is approximately 103% more volatile than AYTU relative to the S&P 500. On balance sheet safety, Aytu BioPharma, Inc. (AYTU) carries a lower debt/equity ratio of 121% versus 3% for ProPhase Labs, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aytu BioPharma, Inc.

(AYTU) is pulling ahead at 1. 8% versus -84. 7% for ProPhase Labs, Inc. (PRPH). On earnings-per-share growth, the picture is similar: NovaBay Pharmaceuticals, Inc. grew EPS 98. 2% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, NBY leads at -1. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aytu BioPharma, Inc.

(AYTU) is the more profitable company, earning -20. 4% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps -20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AYTU leads at -11. 8% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — AYTU leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aytu BioPharma, Inc.

(AYTU) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 27)). NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AYTU: -100. 0%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.